Loading…
← CockpitCompetitor Analysis › 605369.SS Zhejiang Gongdong Medical Technology Co. Ltd. Class AOpen in the cockpit ↗

Zhejiang Gongdong Medical Technology Co. Ltd. Class A605369.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum strong 75
Mkt cap
$542M
US dollars, full cap
Free float
39%
of shares outstanding
$/day
$5.43M
20-day average traded
Fwd P/E
23.5×
forward earnings
ROIC−WACC
+1.8 pp
WACC 8.9%
Hurdle
+4 pp
Req g minus delivered
Next earnings
160 days
27 Apr 2027
Close · CNYCN¥16.69
1D-0.4%
1W-7.3%
1M-6.7%
3M-2.3%
6M-20.9%
YTD-10.6%
1Y-12.8%
ATR %3.7%
52w lowhigh26.4% off high

What Zhejiang Gongdong Medical Technology does

Employees: 1,659

Zhejiang Gongdong Medical Technology at a glance

Size Zhejiang Gongdong Medical Technology (605369.SS) is a China Health Care company (Medical Specialties) with a market value of $542M, the 3495th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.69 on 18 Nov 2026.

Performance Over six months the shares fell 20.9%, against -19.9% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 5.8% over the last twelve months (peer median +7.8%); the operating margin is 8.5% (peer median 2.2%).

Valuation It trades at 23.5× forward earnings against a peer median of 20.4× (4th most expensive of 9).

Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.8 points above its cost of capital (8.9% WACC).

Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026605369.SS 83Peer median 80
Six months, rebased to 100: Zhejiang Gongdong Medical Technology against the median of its 20 peers (local-currency closes).

Zhejiang Gongdong Medical Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.19BCN¥1.13BCN¥1.11BCN¥964MCN¥1.46B
Revenue growth—+2%+15%-34%—
Gross profitCN¥409MCN¥302MCN¥348MCN¥297MCN¥559M
EBITDAn/aCN¥199MCN¥249MCN¥194MCN¥365M
Net incomeCN¥71.5MCN¥51.5MCN¥172MCN¥109MCN¥326M
Free cash flowCN¥192MCN¥142MCN¥108MCN¥63.7MCN¥113M
Capital expenditureCN¥133MCN¥112MCN¥110MCN¥122MCN¥172M
Total debtCN¥177MCN¥179MCN¥52.5MCN¥44.9MCN¥21.2M

Quarterly statements and history in the cockpit →

Zhejiang Gongdong Medical Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%300869ZJYLMYGNRCEL603122301235300439NNNNPACB3006393009527979AVR688075OBIO688580300314TCMD605369.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Gongdong Medical Technology is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%20×40×60×3012353006393009527979688580300314688581TCMD605369.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Gongdong Medical Technology is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%-20%0%20%300869300439300639688075688580688581TCMD605369.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhejiang Gongdong Medical Technology is the large dot.

Zhejiang Gongdong Medical Technology competitors and peer comparison

How Zhejiang Gongdong Medical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Gongdong Medical Technology against its 20 peers (data as of 18 Nov 2026)
Measure605369.SSPeer medianRank in peer set
1-month return-6.7%-5.8%10th lowest of 21
6-month return-20.9%-19.9%11th highest of 21
Distance from 52-week high-26.4%-41.7%6th highest of 21
Revenue growth (TTM)+5.8%+7.8%9th lowest of 21
Operating margin8.5%2.2%7th highest of 21
Forward P/E23.5×20.4×4th most expensive of 9
Growth the price implies (Req g, 7 yrs)10.2%8.4%4th most demanding of 8
Growth delivered (Del g)+6.5%-7.7%3rd highest of 8
Hurdle (Req g minus delivered)+3.7 pp+13.8 pp3rd least demanding of 8
ROIC minus cost of capital+1.8 pp-3.3 pp5th highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%23.5×10.2%+6.5%
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%n/a15.0%-19.8%
Jin Medical International ZJYLUnited States$532M+47%-14%2%n/an/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%n/an/an/a
AVITA Medical RCELUnited States$529M+290%+17%-34%n/an/an/a
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%n/an/an/a
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%33.7×n/an/a
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%2%n/a6.0%-7.7%
Anbio Biotechnology NNNNUnited States$518M-89%+10%67%n/an/an/a
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%n/an/an/a
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%4%57.3×0.4%-13.2%
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%39.7×n/an/a
Shofu 7979.TJapan$510M+32%+9%14%13.2×n/an/a
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%n/an/an/a
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%n/a30.8%-18.6%
Orchestra BioMed OBIOUnited States$587M+87%+1,007%-195%n/an/an/a
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%n/an/an/a
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%19.7×20.1%+4.2%
Ningbo David Medical Device 300314.SZChina$589M+25%+19%11%12.0×n/an/a
Hangzhou AGS MedTech 688581.SSChina$590M-22%-18%33%18.9×0.4%+27.8%
Tactile Systems Technology TCMDUnited States$592M+6%+14%9%21.1×8.4%+12.0%

Questions

Which companies are Zhejiang Gongdong Medical Technology's closest peers?
The cockpit's peer set: Contec Medical Systems (300869.SZ), Jin Medical International (ZJYL), Myriad Genetics (MYGN), AVITA Medical (RCEL), Cowealth Medical China (603122.SS), Wuhan Huakang Century Clean Technology (301235.SZ), MedicalSystem Biotechnology (300439.SZ), Anbio Biotechnology (NNNN).
Is Zhejiang Gongdong Medical Technology expensive compared with its peers?
On forward p/e it trades at 23.5× against a peer median of 20.4×, 4th most expensive of 9 in its peer set. For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Zhejiang Gongdong Medical Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -20.9% against -19.9% for the median peer; over one year -12.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.